Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 12:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Terminated Not applicable Interventional Accepts healthy volunteers

PGC-1 & Muscle Mitochondrial Dysfunction in Diabetes

NCT02282423
Conditions
Diabetes, Obesity
Interventions
Pre-study dietary and exercise instruction., Screening examination and oral glucose tolerance test, Euglycemic clamp, VO2max., Acute exercise bout, Percutaneous needle muscle biopsies
Behavioral · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 59 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Scottsdale, Arizona
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of Ureteral Jets on Cystoscopy

NCT02476448
Conditions
Injury of Ureter
Interventions
Normal saline, Phenazopyridine, Dextrose 10%, Sodium Fluorescein
Drug
Lead sponsor
Cecilia Calvo
Other
Eligibility
18 Years and older · Female only
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Weston, Florida
Conditions
Diabetes
Interventions
insulin regular IV infusion, IV insulin infusion
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
Interventions
TH-302, Gemcitabine, Placebo (5 percent dextrose - D5W)
Drug
Lead sponsor
ImmunoGenesis
Industry
Eligibility
18 Years and older
Enrollment
693 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Rockland, Massachusetts
Conditions
Type1 Diabetes Mellitus
Interventions
AID System, Insulin Lispro
Device · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Renton, Washington
Conditions
Metastatic Cancer, Metastatic Melanoma, Renal Cancer
Interventions
Anti-VEGFR2 CAR CD8 plus PBL, Cyclophosphamide, Aldesleukin, Fludarabine
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Lymphoma, Non-Hodgkin
Interventions
Copanlisib (Aliqopa, BAY80-6946)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
15
States / cities
Birmingham, Alabama • Gilbert, Arizona • Anaheim, California + 12 more
Terminated Phase 2 Interventional Results available

Vitamin B12a Vasoplegic Syndrome

NCT03735316
Conditions
Vasoplegic Syndrome
Interventions
Hydroxocobalamin, Cardiopulmonary Bypass, Placebos
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Leukemia, Lymphoma, Myelodysplastic Syndromes, Osteoporosis, Ovarian Cancer
Interventions
calcium, cholecalciferol, zoledronic acid
Dietary Supplement · Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
2
States / cities
Minneapolis, Minnesota • Madison, Wisconsin
Conditions
Type 1 Diabetes Mellitus
Interventions
Tandem t:slim X2 with Control-IQ Technology + Dexcom G6, Dexcom CGM G5, Continuous Subcutaneous Insulin Infusion
Device
Lead sponsor
University of Virginia
Other
Eligibility
6 Years to 18 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Stanford, California • Aurora, Colorado • Charlottesville, Virginia
Conditions
Type 1 Diabetes Mellitus
Interventions
Investigational inhaled insulin (Technosphere), Artificial Pancreas (AP) device (APS©)
Drug · Device
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
21 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Santa Barbara, California
Conditions
Breast Cancer, Breast Cancer, Female, Breast Cancer, Male, Breast Neoplasms
Interventions
Fluoro-D-glucose-positron Emission Tomography, 2-deoxy-2-[18F]fluoro-D-glucose (FDG), Echocardiogram
Diagnostic Test · Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Effect of GLP-1 on Microvascular Insulin Responses in Type 1 Diabetes

NCT04133922
Conditions
Type 1 Diabetes, Insulin Sensitivity/Resistance
Interventions
GLP-1, Insulin, Dextrose 20 % in Water
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 40 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Lymphoma
Interventions
Rituximab, Cyclophosphamide, Cytarabine, Doxorubicin, Etoposide, Ifosfamide, Leucovorin, Methotrexate, Thalidomide, Vincristine, Mesna, Filgrastim (G-CSF), Granisetron, Decadron
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
1
States / cities
Miami, Florida
Completed Not applicable Interventional Accepts healthy volunteers Results available

Mechanisms of Increased Androgen Production Among Women With Polycystic Ovary Syndrome

NCT00989781
Conditions
Polycystic Ovary Syndrome
Interventions
3-D Ultrasound, recombinant human chorionic gonadotropin, Recombinant human follicle stimulating hormone, Adrenocorticotropin, Dexamethasone, Glucose
Radiation · Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 37 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
San Diego, California
Completed Not applicable Interventional Results available

IV Insulin Protocol in Diabetes and Renal Transplantation

NCT00609986
Conditions
Kidney Transplantation, Diabetes, Hyperglycemia
Interventions
insulin, NPH Insulin or glargine insulin and aspartame insulin
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Metastatic Melanoma, Skin Cancer
Interventions
autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes, ALVAC MART-1 Vaccine, aldesleukin, cyclophosphamide, fludarabine phosphate
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Diabetes Mellitus Type 1
Interventions
iPhone bionic pancreas, iLet bionic pancreas, Xeris Xerisol glucagon, Lilly glucagon, iLet infusion set, Contact Detach infusion set
Device · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Triple Negative Breast Cancer
Interventions
Trilaciclib, Sacituzumab Govitecan-hziy
Drug
Lead sponsor
G1 Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
22
States / cities
Chandler, Arizona • Bakersfield, California • Los Angeles, California + 18 more
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions
oxaliplatin
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
11
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 6 more
Conditions
Breast Cancer
Interventions
Gemcitabine and Carboplatin, P276-00 along with Gemcitabine and carboplatin
Drug
Lead sponsor
Piramal Enterprises Limited
Industry
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
4
States / cities
Burbank, California • La Jolla, California • Sacramento, California + 1 more
Conditions
Type 1 Diabetes Mellitus
Interventions
Hypoglycemia-Hyperglycemia Minimizer System
Device
Lead sponsor
Animas Corporation
Industry
Eligibility
21 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Santa Barbara, California
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin Aspart, Insulin Lispro
Drug
Lead sponsor
Tulane University Health Sciences Center
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
New Orleans, Louisiana
Conditions
Metastatic Cancer, Metastatic Melanoma
Interventions
Anti-NY ESO-1 T cell receptor (TCR) cluster of differentiation 62L (CD62L)+ cells, Aldesleukin, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland